Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2008 15:00 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity to Present At Rodman & Renshaw Annual Global Investment Conference

CAMBRIDGE, Mass., Nov. 5, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Steven H. Holtzman,...
October 29, 2008 17:33 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Advances Its Oncology Portfolio and Announces Third Quarter Financial Results

Infinity initiates Phase 3 international registration trial with potential first-to-market Hsp90 inhibitor, triggering milestone payment Infinity's clinical...
October 29, 2008 15:24 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces Expansion of Phase 2 Clinical Study Evaluating IPI-504 in Advanced Non-Small Cell Lung Cancer

CAMBRIDGE, Mass., Oct. 29, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it has met pre-specified criteria to expand both arms of its ongoing Phase 2...
October 28, 2008 15:10 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces the Promotion of Adelene Q. Perkins to President and Chief Business Officer

CAMBRIDGE, Mass., Oct. 28, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced the promotion of Adelene...
October 24, 2008 11:57 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Initiates International Phase 3 Registration Trial of IPI-504 in Patients With Refractory GIST

CAMBRIDGE, Mass., Oct. 24, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced initiation of a Phase 3 registration trial of IPI-504 (retaspimycin hydrochloride), its...
October 24, 2008 06:10 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity's Hedgehog Pathway Inhibitor IPI-926 Demonstrates Significant Tumor Growth Inhibition in Human Pancreatic Cancer Model

IPI-926 Down-Regulates Hedgehog Signal in Tumor Stroma, Elucidating Potentially Important Role of Inhibiting Tumor-Stromal Interactions to Fight Cancer ...
October 23, 2008 08:10 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Announces Conference Call Discussing R&D Progress and Third Quarter 2008 Results

CAMBRIDGE, Mass., Oct. 23, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that management will host...
October 22, 2008 06:10 ET | Source: Infinity Pharmaceuticals, Inc.

Preclinical Data Show Anti-Tumor Activity With Infinity's Oral Hsp90 Inhibitor IPI-493

GENEVA and CAMBRIDGE, Mass., Oct. 22, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced preclinical data demonstrating anti-tumor activity with IPI-493, Infinity's...
October 16, 2008 06:40 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity Initiates Phase 1 Trial of Novel Hedgehog Pathway Inhibitor, IPI-926

CAMBRIDGE, Mass., Oct. 16, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it has initiated a...
October 14, 2008 08:15 ET | Source: Infinity Pharmaceuticals, Inc.

Infinity to Present New Data On Its Innovative Anti-Cancer Agents At AACR-EORTC-NCI Symposium

CAMBRIDGE, Mass., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that new data from...